BioSpace News Archive

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021 .

IntelGenx Technologies Corp. announced that on December 31, 2020, it issued 887,880 common shares at a deemed price of C$0.335 per Common Share in payment of an aggregate of C$297,440 in interest owing on the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2022.

Owens & Minor, Inc. (NYSE: OMI) announced today that the company will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021.

MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio’s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan). The above-descr

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease. The main cohort of TRANQUILITY is expected to begin enro

CRH Medical Corporation (" CRH ", or the “Company” ) (TSX: CRH) (NYSE MKT: CRHM) today announced that Dr. Tushar Ramani , Chief Executive Officer, and Richard Bear , Chief Financial Officer, will attend the virtually held 2021 Annual ICR Conference from January 12 th to the 14th. Management will participate

The alliance will provide the Diagnostic Imaging® audience with clinical education opportunities and expand the current reach of its editorial content